StockWatch
·
DEEPAK NITRITE LTD.-$ · QQ2 FY-2027 · THE CALL

Record PAT masks AI margin compression; polycarbonate platform de-risks cycles

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q2 FY27 resultsDEEPAKNTRDEEPAK NITRITE LTD.-$04 Nov 2026 · 6 min read
Verdict

Buy

confidence 7/10

Credibility

Grade B

Hit Q2 delivery on phenol; AI margin compression expected as new assets ramp—phasing in line with guidance

Short-term outlook

Optimistic

next 1–2 quarters

Long-term outlook

Very Optimistic

multi-year

Record Q2 delivery (PAT +235% YoY, ₹3,091 Cr revenue) backed by phenol strength and new asset ramps; long-term polycarbonate platform + integrated value chains de-risk commodity cyclicality. Key risk: phenol cycle at peak, AI margin recovery timing uncertain, propylene supply constraints.

₹3091 Cr

Revenue · +61.8% YoY

₹398 Cr

Reported PAT · +234.9% YoY

Compressing

Margins · vs guidance: Mixed

Did the claims hold up?

Management's claims vs. the numbers

Achieved highest ever quarterly revenue and EBITDA

MET

Q2 revenue ₹3,091 Cr (best-ever Q2), consolidated EBITDA ₹643 Cr (+187% YoY)

Phenolics highest ever quarterly revenue

MET

Phenol segment ₹2,291 Cr (+72% YoY, +29% QoQ), confirmed as record

Advanced Intermediates buoyant Q1 demand, margins moderate in Q2

MISS

Q2 revenue ₹811 Cr (flat QoQ), EBIT ₹49 Cr (down 27% QoQ from ₹67 Cr), margin 6%

Phenol 4 lakh tonne capacity sustained

MET

Management: 'come close enough to 4 lakh tonnes plus or minus', constrained by propylene supply

MIBK/MIBC operational by Q2, acetophenone commissioned

MET

Both commissioned Q2; MIBK/MIBC at 60% utilization, acetophenone ramp Q3 onwards

H2 FY27 AI margin recovery expected toward Q1 levels

MET

Management guided Q3 EBIT % 'between Q1 and Q2, closer to Q1' (Q1: 11%, Q2: 6%)

Earnings quality

What changed since the last call

Deltas vs. the prior call

Phenol demand surge extends, now at "peak", not structural growth

Neutral

Q1 call: strong domestic demand. Q2 call: 'geopolitical disruptions + supply tightness favorable, but not a super cycle.' Management reset expectations—peak cycle, not new normal.

Advanced Intermediates margin compression vs Q1 guidance

Downgrade

Q1 implied recovery to 11%+ EBIT margin in Q2; instead Q2 delivered 6% margin. Root: 'lower capacity utilization' due to raw material cost volatility and demand moderation.

Polycarbonate timeline shifted from FY29 to FY30-31

Downgrade

Investor deck implied H2 FY28-29 polycarbonate entry; call confirms FY31 integration. Phenol/BPA commissioning in line, but polycarbonate resin plant delayed.

Capex profile: less FY27, more FY28-30

Neutral

Prior: ₹3.2 Cr FY27 (of ₹11.5 Cr total). Now: ~₹800-900 Cr H2 FY27, ₹2.2-2.4 Cr FY28, ₹2.5 Cr FY28-29. Total ₹11.7 Cr (flat), just re-phased.

MIBK/MIBC launched on-schedule, but ramp slower than hoped

New

Commissioned Q2 as promised, but at 60% utilization targeting 100%. Indicates market absorption or internal yield challenges in early run.

The Q&A

Analysts pressed on AI margin recovery timing, phenol cycle sustainability, and polycarbonate approvals. Management held firm on 14-15% AI EBIT target (steady-state, not imminent), acknowledged phenol cycle peak candidly, and confirmed FY31 polycarbonate. Q&A was detailed but revealed no major concessions.

The exchanges that mattered

AI capacity utilization — Nirav Jimudia, Anvil Wealth

Answered

Q3 EBIT margin expected between Q1 and Q2 levels, closer to Q1 (~11%). New assets ramping gradually; full utilization realization by FY28-29.

Phenol competition dynamics — Archit Joshi, Nuvama

Answered

India's 2 lakh tonne new capacity growth already absorbed. China participates selectively (when imports cheaper). Deepak's debottlenecking + scale moat insulate us. Pricing power holds.

Advanced Intermediates EBIT guidance — Sanjesh Jain, ICICI

Answered

₹240-400 crore in absolute terms at steady-state with 14-15% EBIT margin. New assets contribute ₹250+ Cr incremental EBIT as utilization improves.

Phenol demand and imports — Arun Prasath, Avendus

Answered

India's consumption growing 6-7% annually; demand resilient for chemicals, laminates, autos. China not participating selectively. India's SKU diversity (specialty-grade) commands premium. Wallet share expansion, not commodity dumping.

Polycarbonate approval timeline — Ankur Periwal, Axis

Answered

Approvals are for compounds, not resins. Resins being imported for now. FY31 integrated plant ramp-up; FY32+ selling compounds to the market alongside resin supply.

Capex guidance multi-year — Abhijit Akella, Kotak

Answered

₹2.2-2.4 Cr FY28, ₹2.5 Cr FY28-29, ₹2.5-3 Cr balance FY29-30. Total ₹11.7 Cr. Equity mostly done (~₹50 Cr left), debt funding main lever.

Volume vs price growth mix — Adiya Iyer, HDFC

Partial

Volume roughly flat YoY (Q1 shutdown impact). Growth is price realization + procurement efficiency. Optimal run rate achieved; headroom available but not maxed out.

Acetone captive consumption — Rohit Nagraj, 360 ONE

Answered

Integrated approach: 60-65% consumed captively, balance sold externally. Full utilization dependent on market demand; we optimize for profitability, not volume maximization.

New specialty molecules R&D — Rishabh Tripathi, Multi Dimensional

Answered

CDMO opportunities being explored; R&D from kilo-lab to pilot scale in progress. Early-stage, not material revenue yet. Personal care and specialty laminates high-value focus areas.

China competitive pressure — Vansh Gupta, Prescient

Answered

No significant impact. Propylene/ammonia shortage benefits Indian makers. Integrated approach + multi-SKU moat shields us. India's growth story resilient; China not dominating here.

Guidance

Forward guidance and management's confidence

No explicit FY27 revenue target; H1 ₹5,682 Cr suggests ₹11-12 Cr+ FY27

Medium

Phenol sustains 4 LT; AI recovery in H2 FY27 drives incremental. Propylene supply constrains phenol upside.

Phenol: Sustain 20%+ EBIT margin; commodity cycle risk if feedstock inflation

High

Q2 demonstrated 22% phenol EBIT margin at peak cycle. Management realistic: 'not a super cycle,' but sustained at current levels likely H2 FY27.

AI EBIT margin: Recovery from 6% Q2 to 11% (Q1-like) in Q3; target 14-15% FY28-29

Medium

Dependent on new asset utilization ramp (nitration, etc.) and market absorption. Phased ramp expected; full steady-state ₹240-400 Cr absolute EBIT.

₹2.2-2.4 Cr FY28, ₹2.5 Cr FY28-29, ₹2.5-3 Cr FY29-30, total ₹11.7 Cr over 4 years

High

Equity funding ~done (₹50 Cr left); debt main lever (60:40 debt:equity agreed). Polycarbonate ~60% of capex; rest AI expansion & debottlenecking.

Risks the call surfaced

Ranked by how much they should concern a holder

Phenol cycle peak

High

Phenol at 'peak' driven by geopolitical supply disruptions + freight tightness. Management explicit: 'not a super cycle.' Normalization risks 5-10% margin compression.

AI segment margin recovery timing

High

AI EBIT fell 27% QoQ despite revenue +38% YoY, margin only 6% vs target 14-15%. Recovery dependent on new asset full-load utilization (nitration, etc.) and market absorption. Phased ramp could extend recovery past FY28.

Polycarbonate execution & approval cycle

High

FY31 polycarbonate plant entry is 18 months away; requires feedstock PDH plant commissioning, resin pilot qualification at scale, and customer approvals across 500+ grades. Delay or cost overrun likely given specialty complexity.

Propylene feedstock supply

Medium

Phenol ramp constrained by propylene availability; management notes 'disturbance with regards to propylene availability' in recent months. Non-traditional sourcing required at higher cost; limits margin expansion.

New asset underutilization

Medium

MIBK/MIBC running at 60% utilization (vs target 100%+); acetophenone just launched (Q3 ramp uncertain). If market absorption slower than guided, AI margin recovery delayed; capex returns compressed.

Macro / geopolitical volatility

Medium

Strong Q2 driven by supply-chain disruptions (freight, import tightness, China anti-involution). If geopolitical normalizes (freight costs fall, imports resume), tailwind reverses. Phenol cycle compressed; AI margin pressure.

Management

Score 8/10. Structured, quantified, candid on cycles (phenol peak acknowledgment) and execution risks (propylene supply, polycarbonate delay). NDA shields held where needed (customer names), but specifics on EBIT targets and capex provided. Hit Q2 delivery on phenolics (record revenue/EBIT); AI margin compression expected but timeline slippage on polycarbonate (FY29→FY30-31). Capex on track; equity funding mostly done.

What to watch next
  • 1 · Q3 FY27

    AI EBIT margin recovery toward 11% (Q1 level); acetophenone ramp-up

  • 2 · H2 FY27

    Phenol 4 LT sustained amid propylene supply tightness; MIBK/MIBC move toward 100% utilization

  • 3 · H2 FY27

    REACH registration approval for MIBK/MIBC opens EU export markets

Key risk: phenol cycle at peak, AI margin recovery timing uncertain, propylene supply constraints.

Informational and educational content only. Not investment advice.